In 2002, a study reported by Liu et al. revealed that a clinical RA drug of Xinfeng capsule (XFC, 1.8 g/kg, p.o.)possessed significant anti-RA effects in rats via reduction of arthritis index, and the potential mechanisms are correlated to up-regulation of Fas and FasL, whereas down-regulation of Bcl-2 in synovia tissues of joints [40]. This evidence concerns the gene FAS and rheumatoid arthritis.